Poor
Not Aligned
Patient Risk:
Moderate
Summary
Only a subset of the interaction/muscle-related concepts in the provided claims is supported by the label excerpts (notably increased myopathy risk with certain interacting drugs and holding/discontinuing for serious myopathy/rhabdomyolysis risk). Many other claims (bleeding, cognitive impairment, falls, SSRI mechanism, and broad elderly interaction assertions) are not supported by the supplied LIPITOR label excerpts.
Category Scores
Accurate Statements
The risk of myopathy during treatment with statins is increased with concurrent administration of fibric acid derivatives, lipid-modifying doses of niacin, cyclosporine, or strong CYP 3A4 inhibitors (e.g., clarithromycin, HIV protease inhibitors, and itraconazole).
5.1 Skeletal Muscle (paragraph: risk increased with concurrent administration of cyclosporine, fibric acid derivatives, erythromycin/clarithromycin, combination of ritonavir plus saquinavir or lopinavir plus ritonavir, niacin, or azole antifungals); and 7 Drug Interactions excerpt referencing increased risk of myopathy with these agents (e.g., clarithromycin, HIV protease inhibitors, itraconazole).
Concomitant use of higher doses of atorvastatin with cyclosporine and strong CYP 3A4 inhibitors increases risk of myopathy/rhabdomyolysis.
5.1 Skeletal Muscle (paragraph stating concomitant use of higher doses with cyclosporine and strong CYP3A4 inhibitors increases risk of myopathy/rhabdomyolysis); and Table 1 prescribing recommendations for interacting agents.
LIPITOR therapy should be temporarily withheld or discontinued in any patient with an acute, serious condition suggestive of a myopathy or having a risk factor predisposing to renal failure secondary to rhabdomyolysis.
5.1 Skeletal Muscle (paragraph beginning: "LIPITOR therapy should be temporarily withheld or discontinued...").
Unsupported Statements
SSRIs are antidepressant medications that work by increasing serotonin levels in the brain.
No SSRI description or mechanism is provided in the supplied LIPITOR label excerpts.
Lipitor (atorvastatin) is a statin medication used to lower cholesterol levels.
The supplied excerpts do not include indication/mechanism statements for Lipitor.
Lipitor (atorvastatin) belongs to the class of HMG-CoA reductase inhibitors.
The provided excerpts do not state this classification.
Taking SSRIs and Lipitor together can increase the risk of adverse effects, particularly in elderly patients.
No interaction guidance between SSRIs and Lipitor is present in the provided excerpts, and no label support is shown for this SSRI-specific elderly interaction claim.
The combination of SSRIs and Lipitor can increase the risk of bleeding, particularly gastrointestinal bleeding.
No bleeding/GI bleeding interaction information with SSRIs is present in the supplied excerpts.
Lipitor can cause muscle damage, particularly in older adults.
While myopathy risk is discussed, the excerpt provided does not state that muscle damage occurs particularly in older adults.
When taken with SSRIs, the risk of muscle damage may be increased.
No SSRI-specific muscle interaction is provided in the excerpts.
The combination of SSRIs and Lipitor may increase the risk of cognitive impairment in the elderly.
The provided excerpts mention memory impairment as a postmarketing adverse reaction, but do not support SSRI + Lipitor or specifically elderly interaction-related cognitive impairment.
The combination of SSRIs and Lipitor may increase the risk of falls in the elderly.
No falls-related information is provided in the supplied excerpts.
SSRIs and Lipitor can increase the risk of bleeding in the elderly.
No label support for SSRI + Lipitor bleeding risk in the elderly is present in the excerpts.
SSRIs and Lipitor can increase the risk of muscle damage in the elderly.
No SSRI + Lipitor muscle interaction is provided in the excerpts.
SSRIs and Lipitor can increase the risk of cognitive impairment in the elderly.
No SSRI + Lipitor elderly cognitive impairment interaction is provided in the excerpts.
SSRIs and Lipitor can increase the risk of falls in the elderly.
No falls-related information is provided in the excerpts.
Taking Lipitor with other medications, including SSRIs, can increase the risk of bleeding.
No bleeding interaction information with SSRIs is provided in the excerpts.
Taking Lipitor with other medications, including SSRIs, can increase the risk of muscle damage.
No SSRI interaction information for myopathy is provided in the excerpts; label support is limited to specific interacting agents listed (e.g., cyclosporine, fibric acid derivatives, niacin, certain CYP3A4 inhibitors).
Taking Lipitor with other medications, including SSRIs, can increase the risk of cognitive impairment.
The excerpts do not describe cognitive impairment as an interaction outcome, nor do they connect it to SSRIs.
It is generally not recommended to take Lipitor with other statins because this can increase the risk of adverse effects.
No such recommendation is present in the supplied excerpts.
The elderly are at a higher risk of adverse effects from medication interactions due to age-related changes.
The excerpt only states advanced age is a predisposing factor for myopathy and that greater sensitivity cannot be ruled out; it does not support this broader mechanism statement.
The elderly are at a higher risk of adverse effects from medication interactions due to polypharmacy.
No label support regarding polypharmacy as a cause of increased interaction risk is provided in the excerpts.
The elderly are at a higher risk of adverse effects from medication interactions due to comorbidities.
No label support regarding comorbidities as a cause of increased interaction risk is provided in the excerpts.
Contradictions
Important Omissions
Specific elderly interaction framing grounded in label language (e.g., label-supported caution in elderly due to advanced age being a predisposing factor for myopathy).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several claims introduce unsupported interaction risks (bleeding, falls, cognitive impairment) involving SSRIs, which are not supported by the provided LIPITOR label excerpts. Unsupported claims could mislead risk assessment if treated as label-grounded.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple SSRI-related and elderly-specific interaction claims (bleeding, cognitive impairment, falls) are not supported by the supplied LIPITOR prescribing information excerpts; only statin myopathy/rhabdomyolysis interaction concepts with specific listed drugs are supported.
Suggested Improvement
Restrict claims to what the excerpted label supports (increased myopathy risk with specified interacting agents like cyclosporine/fibric acid derivatives/niacin/strong CYP3A4 inhibitors; and label-supported cautious use in elderly due to advanced age as a predisposing factor for myopathy). Remove or qualify unsupported SSRI-specific and non-myopathy outcomes (bleeding, falls, cognitive impairment) unless corresponding label text is provided.